New Leukemia Treatment Breakthrough: Adding Blinatumomab Significantly Improves Outcomes for Children

A groundbreaking study has revealed exciting news for families affected by childhood leukemia. After nearly two decades of limited progress in improving outcomes for children with B-cell acute lymphoblastic leukemia (B-ALL), researchers have achieved a breakthrough that could change how the most common childhood cancer is treated.

"Adding blinatumomab was not only better, it was a home run," says Dr. Rachel Rau, the study's co-lead author from Seattle Children's Hospital. "It led to improvements in outcomes beyond even our own expectations."

What the Study Found

While current treatments for childhood B-ALL already achieve impressive survival rates of 85-90%, leukemia doctors have been searching for ways to prevent relapses, which remain a leading cause of cancer-related deaths in children. Particularly concerning is that about half of all relapses occur in children initially classified as standard-risk.

The research, presented at the 2024 American Society of Hematology (ASH) meeting, showed remarkable results:

• Children who received blinatumomab with their standard chemotherapy were 61% less likely to experience cancer recurrence or death

• After three years, 96% of children who received blinatumomab remained leukemia-free, compared to 87.9% with standard treatment alone

• The benefits were seen across all patient groups, regardless of their risk level, genetic factors, gender, or ethnic background

Safety: A Critical Consideration

The study demonstrated a reassuring safety profile, and blinatumomab was generally well-tolerated by children:

• No treatment-related deaths

• Very low rates of serious side effects:

  • Only 0.3% experienced severe cytokine release syndrome

  • Less than 1% (0.7%) experienced seizures

  • While there were some increased risks of fever and infections, these were manageable with proper medical care

Why This Matters

While current treatments for childhood B-ALL are already quite effective, with survival rates between 85-90%, relapse remains a serious concern. This new approach could help prevent relapses, which are particularly challenging to treat and remain a leading cause of cancer-related deaths in children.

The new findings suggest blinatumomab should become the standard first-line treatment for most newly diagnosed patients.

Who Could Benefit

This new treatment approach could help approximately two-thirds of children diagnosed with B-ALL each year. However, children with the most favorable risk profile may not need this additional treatment.

Watch our interview with Dr. Rau below for insights on which patients could benefit the most from blinatumomab consolidation treatment. 

Expert Perspective

Listen to Dr. Rau's interview, where she discusses:

• How this treatment changed clinical practice overnight

• Specific side effects observed in children treated with blinatumomab

• Treatment administration challenges and future alternatives

• Details about patient selection

Looking Ahead

The results were so promising that the study stopped randomizing patients because the benefits of blinatumomab were clear. However, there are important considerations for families to discuss with their healthcare teams:

• The treatment requires continuous intravenous administration

• Access and logistics can be challenging, particularly for families living far from treatment centers

• Researchers are working on newer formulations, including subcutaneous options, to make treatment more convenient

• Future studies will explore if some chemotherapy components could be reduced while maintaining these excellent outcomes

Researchers, hospitals, the pharmaceutical industry, and regulatory agencies are now working on making this treatment more accessible to all eligible patients.

Subscribe to our newsletter below to stay up to date with the latest advancements in acute lymphoblastic leukemia treatment:

Subscribe to ALL Newsletter

Sources: 

• Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children